Literature DB >> 25289568

The structural basis for mTOR function.

Domagoj Baretić1, Roger L Williams2.   

Abstract

The phosphoinositide 3-kinase (PI3K) related protein kinases (PIKKs) are a family of protein kinases with a diverse range of vital cellular functions. Recent high-resolution crystal structures of the protein kinase mTOR suggest general architectural principles that are likely to be common to all of the PIKKs. Furthermore, the structures make clear the close relationship of the PIKKs to the PI3Ks. However, the structures also make clear the unique features of mTOR that enable its substrate specificity. The active site is deeply recessed and flanked by structural elements unique to the PIKKs, namely, the FRB domain, the LST8 binding element, and a C-terminal stretch of helices known as the FATC domain. The FRB has a conserved element in it that is part of a bipartite substrate recognition mechanism that is probably characteristic of all of the PIKKs. The FRB also binds the mTOR inhibitor rapamycin that has been referred to as an allosteric inhibitor, implying that this inhibitor is actually a competitive inhibitor of the protein substrate. This bipartite substrate-binding site also helps clarify how rapamycin can result in substrate-specific inhibition.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  4E-BP1; PI3K; PIKK; Rapamycin; S6K1; mTOR

Mesh:

Substances:

Year:  2014        PMID: 25289568     DOI: 10.1016/j.semcdb.2014.09.024

Source DB:  PubMed          Journal:  Semin Cell Dev Biol        ISSN: 1084-9521            Impact factor:   7.727


  18 in total

Review 1.  Emerging roles of aerobic glycolysis in breast cancer.

Authors:  Z Wu; J Wu; Q Zhao; S Fu; J Jin
Journal:  Clin Transl Oncol       Date:  2019-07-29       Impact factor: 3.405

2.  RAPTOR Controls Developmental Growth Transitions by Altering the Hormonal and Metabolic Balance.

Authors:  Mohamed A Salem; Yan Li; Krzysztof Bajdzienko; Joachim Fisahn; Mutsumi Watanabe; Rainer Hoefgen; Mark Aurel Schöttler; Patrick Giavalisco
Journal:  Plant Physiol       Date:  2018-04-23       Impact factor: 8.340

3.  The Transcription Factor Bach2 Is Phosphorylated at Multiple Sites in Murine B Cells but a Single Site Prevents Its Nuclear Localization.

Authors:  Ryo Ando; Hiroki Shima; Toru Tamahara; Yoshihiro Sato; Miki Watanabe-Matsui; Hiroki Kato; Nicolas Sax; Hozumi Motohashi; Keiko Taguchi; Masayuki Yamamoto; Masaki Nio; Tatsuya Maeda; Kyoko Ochiai; Akihiko Muto; Kazuhiko Igarashi
Journal:  J Biol Chem       Date:  2015-11-30       Impact factor: 5.157

4.  A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma.

Authors:  QiWen Fan; Ozlem Aksoy; Robyn A Wong; Shirin Ilkhanizadeh; Chris J Novotny; William C Gustafson; Albert Yi-Que Truong; Geraldine Cayanan; Erin F Simonds; Daphne Haas-Kogan; Joanna J Phillips; Theodore Nicolaides; Masanori Okaniwa; Kevan M Shokat; William A Weiss
Journal:  Cancer Cell       Date:  2017-03-13       Impact factor: 31.743

5.  Bipartite binding and partial inhibition links DEPTOR and mTOR in a mutually antagonistic embrace.

Authors:  Maren Heimhalt; Alex Berndt; Jane Wagstaff; Madhanagopal Anandapadamanaban; Olga Perisic; Sarah Maslen; Stephen McLaughlin; Conny Wing-Heng Yu; Glenn R Masson; Andreas Boland; Xiaodan Ni; Keitaro Yamashita; Garib N Murshudov; Mark Skehel; Stefan M Freund; Roger L Williams
Journal:  Elife       Date:  2021-09-14       Impact factor: 8.140

Review 6.  The mTOR signalling cascade: paving new roads to cure neurological disease.

Authors:  Peter B Crino
Journal:  Nat Rev Neurol       Date:  2016-06-24       Impact factor: 42.937

Review 7.  Role of PI3K/Akt signaling pathway in cardiac fibrosis.

Authors:  Wuming Qin; Linghui Cao; Isaac Yaw Massey
Journal:  Mol Cell Biochem       Date:  2021-07-10       Impact factor: 3.396

8.  Transcriptomic analysis of crustacean molting gland (Y-organ) regulation via the mTOR signaling pathway.

Authors:  S Shyamal; S Das; A Guruacharya; D L Mykles; D S Durica
Journal:  Sci Rep       Date:  2018-05-09       Impact factor: 4.379

9.  Potential new therapy of Rapalink-1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma.

Authors:  Kazuki Kuroshima; Hirofumi Yoshino; Shunsuke Okamura; Masafumi Tsuruda; Yoichi Osako; Takashi Sakaguchi; Satoshi Sugita; Shuichi Tatarano; Masayuki Nakagawa; Hideki Enokida
Journal:  Cancer Sci       Date:  2020-05-05       Impact factor: 6.716

10.  Target of Rapamycin (TOR) Negatively Regulates Ethylene Signals in Arabidopsis.

Authors:  Fengping Zhuo; Fangjie Xiong; Kexuan Deng; Zhengguo Li; Maozhi Ren
Journal:  Int J Mol Sci       Date:  2020-04-12       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.